Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Olivier CB"" wg kryterium: Autor


Tytuł :
Kidney Adaptations Prevent Loss of Trace Elements in Wistar Rats with Early Metabolic Syndrome.
Autorzy :
Sánchez-Solís CN; Laboratorio de Investigaciones Químico Clínicas, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Hernández-Fragoso H; Laboratorio de Investigaciones Químico Clínicas, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Aburto-Luna V; Laboratorio de Investigaciones Químico Clínicas, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Olivier CB; Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México, Mexico.
Diaz A; Departamento de Farmacia, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Brambila E; Laboratorio de Investigaciones Químico Clínicas, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Treviño S; Laboratorio de Investigaciones Químico Clínicas, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico. .; Laboratorio de Investigaciones Químico Clínicas, Departamento de Química Clínica, Facultad de Ciencias Químicas, Universidad Autónoma de Puebla, 14 Sur. FCQ1, Ciudad Universitaria, C.P.72560, Puebla, Mexico. .
Pokaż więcej
Źródło :
Biological trace element research [Biol Trace Elem Res] 2021 May; Vol. 199 (5), pp. 1941-1953. Date of Electronic Publication: 2020 Aug 13.
Typ publikacji :
Journal Article
MeSH Terms :
Kidney Diseases*
Metabolic Syndrome*
Trace Elements*
Animals ; Kidney ; Male ; Rats ; Rats, Wistar
Czasopismo naukowe
Tytuł :
Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.
Autorzy :
Leef GC; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Perino AC; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Askari M; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Fan J; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Ho PM; Veterans Affairs Eastern Colorado Health Care System, Denver, CO, USA.; University of Colorado School of Medicine, Denver, CO, USA.
Olivier CB; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Longo L; Department of Veteran Affairs, Pharmacy Benefits Management Services, USA.
Mahaffey KW; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Turakhia MP; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.; Center for Digital Health, Stanford University School of Medicine, Stanford, CA, USA.
Pokaż więcej
Źródło :
Journal of pharmacy practice [J Pharm Pract] 2020 Oct; Vol. 33 (5), pp. 647-653. Date of Electronic Publication: 2019 Feb 21.
Typ publikacji :
Journal Article
MeSH Terms :
Atrial Fibrillation*/diagnosis
Atrial Fibrillation*/drug therapy
Stroke*/drug therapy
Administration, Oral ; Aged ; Anticoagulants/therapeutic use ; Cohort Studies ; Humans ; Retrospective Studies ; Veterans Health
Czasopismo naukowe
Tytuł :
Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study.
Autorzy :
Heger LA; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Danzer M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bode C; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hortmann M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Moser M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
Frontiers in medicine [Front Med (Lausanne)] 2020 Sep 30; Vol. 7, pp. 414. Date of Electronic Publication: 2020 Sep 30 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.
Autorzy :
Olivier CB; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.; Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center, University of Freiburg, Freiburg, Germany.
Sundaram V; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Chertow GM; Division of Nephrology, School of Medicine, Stanford University, Stanford, CA, USA.
Shashidhar S; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
McDonnell LK; Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Ding VY; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Desai M; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Mahaffey KW; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Mell M; Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.; Division of Vascular Surgery, University of California at Davis, Sacramento, CA, USA.
Pokaż więcej
Źródło :
The journal of vascular access [J Vasc Access] 2020 Jul; Vol. 21 (4), pp. 467-474. Date of Electronic Publication: 2019 Nov 27.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Arteriovenous Shunt, Surgical*/adverse effects
Renal Dialysis*/adverse effects
Kidney Failure, Chronic/*therapy
Lactones/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Pyridines/*therapeutic use
Upper Extremity/*blood supply
Aged ; California ; Double-Blind Method ; Early Termination of Clinical Trials ; Female ; Hemorrhage/chemically induced ; Humans ; Kidney Failure, Chronic/diagnosis ; Lactones/adverse effects ; Male ; Middle Aged ; Pilot Projects ; Platelet Aggregation Inhibitors/adverse effects ; Pyridines/adverse effects ; Receptor, PAR-1/antagonists & inhibitors ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Anticoagulation and anaemia: old opponents from the era of VKA?
Autorzy :
Bode C; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2019 Dec 07; Vol. 40 (46), pp. 3791-3792.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anemia*
Atrial Fibrillation*
Anticoagulants ; Cohort Studies ; Humans ; Vitamin K
Opinia redakcyjna
Tytuł :
Is Bleeding Always Bad?: Bad Boy Bleeding.
Autorzy :
Bode C; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany. Electronic address: .
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany.
Pokaż więcej
Źródło :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2019 Sep 24; Vol. 74 (12), pp. 1529-1531.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Peripheral Arterial Disease*
Rivaroxaban*
Aspirin ; Factor Xa Inhibitors ; Hemorrhage ; Humans ; Male
Opinia redakcyjna
Tytuł :
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Autorzy :
Olivier CB; Department of Medicine, Stanford Center for Clinical Research (C.B.O., K.W.M.), Stanford University School of Medicine, CA.; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (C.B.O.).
Fan J; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Askari M; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Mahaffey KW; Department of Medicine, Stanford Center for Clinical Research (C.B.O., K.W.M.), Stanford University School of Medicine, CA.
Heidenreich PA; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Perino AC; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Leef GC; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Ho PM; Division of Cardiology, Denver VA Medical Center, CO (P.M.H.).
Harrington RA; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Department of Medicine, Center for Digital Health (R.A.H., M.P.T.), Stanford University School of Medicine, CA.
Turakhia MP; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Department of Medicine, Center for Digital Health (R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Aug; Vol. 12 (8), pp. e007604. Date of Electronic Publication: 2019 Aug 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/mortality
Anticoagulants/*administration & dosage
Atrial Fibrillation/*drug therapy
Coronary Artery Disease/*therapy
Fibrinolytic Agents/*administration & dosage
Healthcare Disparities/*trends
Platelet Aggregation Inhibitors/*administration & dosage
Practice Patterns, Physicians'/*trends
Purinergic P2Y Receptor Antagonists/*administration & dosage
Stroke/*prevention & control
Aged ; Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/mortality ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Drug Utilization/trends ; Female ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Stroke/diagnosis ; Stroke/mortality ; Time Factors ; Treatment Outcome ; United States/epidemiology ; United States Department of Veterans Affairs ; Veterans Health
Czasopismo naukowe
Tytuł :
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Autorzy :
Olivier CB; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (C.B.O., K.W.M.).; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (C.B.O.).
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
Leonardi S; University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy (S.L.).
Stone GW; Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY (G.W.S.).
Gibson CM; Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.).
Steg PG; FACT (French Alliance for Cardiovascular Clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.).
Hamm CW; Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.).
Wilson MD; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Mangum S; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Price MJ; Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.).
Prats J; Elysis Llc, Carlisle, MA (J.P.).
White HD; Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Lopes RD; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Harrington RA; Department of Medicine, Stanford University School of Medicine, Stanford, CA (R.A.H.).
Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (C.B.O., K.W.M.).
Pokaż więcej
Corporate Authors :
CHAMPION PHOENIX Investigators *
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Jul; Vol. 12 (7), pp. e007342. Date of Electronic Publication: 2019 Jul 12.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Research Design*
Adenosine Monophosphate/*analogs & derivatives
Coronary Artery Disease/*therapy
Coronary Thrombosis/*prevention & control
Myocardial Infarction/*prevention & control
Percutaneous Coronary Intervention/*adverse effects
Platelet Aggregation Inhibitors/*therapeutic use
Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/therapeutic use ; Coronary Artery Disease/complications ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Coronary Thrombosis/diagnosis ; Coronary Thrombosis/etiology ; Coronary Thrombosis/mortality ; Humans ; Myocardial Infarction/diagnosis ; Myocardial Infarction/etiology ; Myocardial Infarction/mortality ; Percutaneous Coronary Intervention/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.
Autorzy :
Yong CM; Division of Cardiology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, California.; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California.
Sundaram V; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Abnousi F; Division of Cardiology, Veterans Affairs Palo Alto Healthcare System, Palo Alto, California.
Olivier CB; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, California.; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Yang J; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Stone GW; Cardiovascular Research Foundation, Columbia University Medical Center, New York, New York.
Steg PG; DHU (Département Hospitalo-Universitaire)-FIRE (Fibrosis, Inflammation, REmodelling), Hôpital Bichat, AP-HPb (Assistance Publique-Hôpitaux de Paris), Université Paris-Diderot, Sorbonne-Paris Cité, and FACT (French Alliance for Cardiovascular clinical Trials), an F-CRIN network, INSERM U-1148, Paris, France.; NLHI, ICMS, Royal Brompton Hospital, Imperial College, London, UK.
Michael Gibson C; Beth Israel Deaconess Medical Center, Division of Cardiology, Harvard Medical School, Boston, Boston, Massachusetts.
Hamm CW; Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
Price MJ; Scripps Clinic and Scripps Translational Science Institute, La Jolla, California.
Deliargyris EN; Science and Strategy Consulting Group, Basking Ridge, New Jersey.
Prats J; Elysis, Carlisle, Massachusetts.
White HD; Auckland City Hospital, University of Auckland, Auckland, New Zealand.
Harrington RA; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, California.
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, Massachusetts.
Mahaffey KW; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, California.
Pokaż więcej
Corporate Authors :
CHAMPION PHOENIX Investigators
Źródło :
Clinical cardiology [Clin Cardiol] 2019 Jun 29. Date of Electronic Publication: 2019 Jun 29.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Autorzy :
Olivier CB; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Mulder H; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Hiatt WR; Division of Cardiology, University of Colorado School of Medicine, Aurora.; CPC Clinical Research, University of Colorado School of Medicine, Aurora.
Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Fowkes FGR; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.
Rockhold FW; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Berger JS; Department of Medicine, New York University School of Medicine, New York.; Department of Surgery, New York University School of Medicine, New York.
Baumgartner I; Swiss Cardiovascular Center, Inselspital, University of Bern, Bern, Switzerland.
Held P; AstraZeneca Gothenburg, Mölndal, Sweden.
Katona BG; AstraZeneca Gaithersburg, Gaithersburg, Maryland.
Norgren L; Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Blomster J; Turku University Hospital, Turku, Finland.
Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Pokaż więcej
Źródło :
JAMA cardiology [JAMA Cardiol] 2019 Jan 01; Vol. 4 (1), pp. 7-15.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Extremities/*blood supply
Myocardial Infarction/*epidemiology
Peripheral Arterial Disease/*complications
Aged ; Ankle Brachial Index/methods ; Clopidogrel/therapeutic use ; Coronary Artery Bypass/methods ; Death ; Extremities/pathology ; Female ; Hospitalization ; Humans ; Incidence ; Ischemia ; Male ; Middle Aged ; Myocardial Infarction/classification ; Myocardial Infarction/mortality ; Myocardial Infarction/therapy ; Percutaneous Coronary Intervention/methods ; Peripheral Arterial Disease/drug therapy ; Peripheral Arterial Disease/therapy ; Platelet Aggregation Inhibitors/therapeutic use ; Risk Factors ; Ticagrelor/therapeutic use
Czasopismo naukowe
Tytuł :
Moderate ischemic mitral regurgitation: coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve.
Autorzy :
Rilinger J; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany - .
Heilmann C; University of Cooperative Education, Plauen, Germany.
Beitinger U; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Diehl P; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Beyersdorf F; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Siepe M; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
The Journal of cardiovascular surgery [J Cardiovasc Surg (Torino)] 2018 Dec; Vol. 59 (6), pp. 830-835. Date of Electronic Publication: 2018 Mar 12.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Coronary Artery Bypass*/adverse effects
Coronary Artery Bypass*/mortality
Heart Valve Prosthesis Implantation*/adverse effects
Heart Valve Prosthesis Implantation*/mortality
Mitral Valve Annuloplasty*/adverse effects
Mitral Valve Annuloplasty*/mortality
Mitral Valve/*surgery
Mitral Valve Insufficiency/*surgery
Myocardial Ischemia/*surgery
Aged ; Aged, 80 and over ; Female ; Germany ; Hemodynamics ; Humans ; Male ; Middle Aged ; Mitral Valve/diagnostic imaging ; Mitral Valve/physiopathology ; Mitral Valve Insufficiency/diagnostic imaging ; Mitral Valve Insufficiency/mortality ; Mitral Valve Insufficiency/physiopathology ; Myocardial Ischemia/diagnostic imaging ; Myocardial Ischemia/mortality ; Myocardial Ischemia/physiopathology ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.
Autorzy :
Olivier CB; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Sundaram V; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.
Leonardi S; Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Lopes RD; Duke University Medical Center, Durham, NC, USA.
Ding VY; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Yang L; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stone GW; Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY, USA.
Steg PG; FACT (French Alliance for Cardiovascular clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, UK.
Gibson CM; Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA, USA.
Hamm CW; Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
Price MJ; Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA.
White HD; Green Lane Cardiovascular Service, Auckland, New Zealand.
Desai M; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Lynch DR Jr; University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Harrington RA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mahaffey KW; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: .
Pokaż więcej
Corporate Authors :
CHAMPION PLATFORM and CHAMPION PCI Investigators
Źródło :
International journal of cardiology [Int J Cardiol] 2018 Nov 01; Vol. 270, pp. 96-101. Date of Electronic Publication: 2018 Jun 08.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Myocardial Infarction/*mortality
Myocardial Infarction/*surgery
Percutaneous Coronary Intervention/*mortality
Perioperative Care/*mortality
Cohort Studies ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Male ; Mortality/trends ; Myocardial Infarction/diagnosis ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/trends ; Perioperative Care/trends ; Time Factors
Czasopismo naukowe
Tytuł :
Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome.
Autorzy :
Olivier CB; a Stanford Center for Clinical Research (SCCR), Department of Medicine , Stanford University School of Medicine , Stanford , CA , USA.; b Center for Digital Health, Department of Medicine , Stanford University School of Medicine , Stanford , CA , USA.
Turakhia MP; b Center for Digital Health, Department of Medicine , Stanford University School of Medicine , Stanford , CA , USA.; c Veterans Affairs Palo Alto Health Care System , Palo Alto , CA , USA.
Mahaffey KW; a Stanford Center for Clinical Research (SCCR), Department of Medicine , Stanford University School of Medicine , Stanford , CA , USA.
Pokaż więcej
Źródło :
Expert opinion on drug safety [Expert Opin Drug Saf] 2018 Mar; Vol. 17 (3), pp. 251-258. Date of Electronic Publication: 2018 Jan 24.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anticoagulants/*administration & dosage
Atrial Fibrillation/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Acute Coronary Syndrome/drug therapy ; Anticoagulants/adverse effects ; Coronary Artery Disease/therapy ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Practice Guidelines as Topic ; Stents ; Thromboembolism/prevention & control
Czasopismo naukowe
Tytuł :
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.
Autorzy :
Rilinger J; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Charlet A; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Esser JS; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Nov; Vol. 42 (4), pp. 558-65.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Observational Study
MeSH Terms :
Atrial Fibrillation*/blood
Atrial Fibrillation*/therapy
Receptors, Purinergic P2Y12*
Stents*
Thromboembolism*/blood
Thromboembolism*/prevention & control
Blood Platelets/*metabolism
Platelet Activation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Aged ; Aged, 80 and over ; Coronary Vessels ; Drug Therapy, Combination ; Female ; Humans ; Male ; Risk Factors
Czasopismo naukowe
Tytuł :
MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation.
Autorzy :
Zhou Q; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Einert M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Schmitt H; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Wang Z; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Pankratz F; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Bode C; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Liao JK; Section of Cardiology, University of Chicago Medical Center, Chicago, IL, USA. Electronic address: .
Moser M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany. Electronic address: .
Pokaż więcej
Źródło :
Vascular pharmacology [Vascul Pharmacol] 2016 Sep; Vol. 84, pp. 67-73. Date of Electronic Publication: 2016 Jul 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Inflammation/*drug therapy
Metalloporphyrins/*pharmacology
Vascular Diseases/*pathology
Animals ; Bone Morphogenetic Protein Receptors, Type II/genetics ; Cell Adhesion ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Human Umbilical Vein Endothelial Cells ; Inflammation/pathology ; Leukocytes/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Signal Transduction/drug effects ; Smad Proteins/metabolism ; Superoxide Dismutase/metabolism ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Aug; Vol. 42 (2), pp. 161-6.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Dabigatran/*pharmacology
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*therapeutic use
Rivaroxaban/*pharmacology
Adenosine Diphosphate/metabolism ; Antithrombins/pharmacology ; Antithrombins/therapeutic use ; Arachidonic Acid/metabolism ; Clopidogrel ; Dabigatran/therapeutic use ; Drug Therapy, Combination ; Humans ; Rivaroxaban/therapeutic use ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University Freiburg, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Jul; Vol. 42 (1), pp. 84-9.
Typ publikacji :
Journal Article
MeSH Terms :
Body Weight*
Platelet Activation/*drug effects
Purinergic P2Y Receptor Antagonists/*administration & dosage
Adenosine/administration & dosage ; Adenosine/analogs & derivatives ; Clopidogrel ; Dose-Response Relationship, Drug ; Drug Dosage Calculations ; Humans ; Platelet Aggregation/drug effects ; Prasugrel Hydrochloride/administration & dosage ; Purinergic P2Y Receptor Antagonists/pharmacology ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Ticagrelor ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.
Autorzy :
Olivier CB; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Meyer M; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Bauer H; Munich University Hospital, Institute and Outpatient Clinic for Occupational, Social, and Environmental Medicine, Munich, Germany.
Schnabel K; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Weik P; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Zhou Q; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Bode C; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Moser M; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Diehl P; Heart Center Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2016 Feb 17; Vol. 11 (2), pp. e0149053. Date of Electronic Publication: 2016 Feb 17 (Print Publication: 2016).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenosine Diphosphate/*pharmacology
Oligopeptides/*pharmacology
Platelet Aggregation/*drug effects
Receptors, Purinergic P2Y12/*metabolism
Aged ; Biomarkers/metabolism ; Female ; Humans ; Male ; Platelet Count ; Regression Analysis
Czasopismo naukowe
Tytuł :
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Autorzy :
Olivier CB; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany. Electronic address: Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Meyer M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Anto-Michel N; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Diehl P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Zhou Q; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Geisen U; Medical Center-University of Freiburg, Institute for Clinical Chemistry and Laboratory Medicine, Freiburg, Germany.
Bode C; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Moser M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2016 Feb; Vol. 138, pp. 63-68. Date of Electronic Publication: 2015 Nov 01.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antithrombins/*therapeutic use
Atrial Fibrillation/*drug therapy
Blood Platelets/*drug effects
Dabigatran/*therapeutic use
Platelet Aggregation/*drug effects
Receptors, Thrombin/*metabolism
Rivaroxaban/*therapeutic use
Aged ; Aged, 80 and over ; Antithrombins/pharmacology ; Dabigatran/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Pulmonary Embolism/drug therapy ; Rivaroxaban/pharmacology ; Venous Thrombosis/drug therapy
Czasopismo naukowe
Tytuł :
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany, christoph.olivier@universitaets-herzzentrum.de.
Schnabel K
Brandt C
Weik P
Olschewski M
Zhou Q
Bode C
Diehl P
Moser M
Pokaż więcej
Źródło :
Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2014 Dec; Vol. 103 (12), pp. 968-75. Date of Electronic Publication: 2014 Jul 16.
Typ publikacji :
Journal Article; Observational Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Myocardial Revascularization*
Stents*
Adenosine Diphosphate/*blood
Coronary Artery Disease/*surgery
Peptide Fragments/*blood
Platelet Aggregation/*physiology
Postoperative Complications/*mortality
Aged ; Coronary Artery Disease/blood ; Coronary Artery Disease/mortality ; Female ; Follow-Up Studies ; Germany/epidemiology ; Humans ; Male ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Function Tests ; Prospective Studies ; Receptors, Cell Surface ; Survival Rate/trends ; Ticlopidine/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies